BCM
ICPT

BlueCrest Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BlueCrest Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,469
Closed -$518K – 1180
2015
Q4 		$518K Buy
+3,469
New +$587K 0.02% 571
2015
Q2 		– Sell
-1,000
Closed -$282K – 953
2015
Q1 		$282K Buy
+1,000
New +$217K 0.02% 533

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlueCrest Capital Management's ICPT Position: Q1 2016 in Review

BlueCrest Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2016, closing a stake of 3,469 shares — an estimated $518K sold.

BlueCrest Capital Management first reported a position in ICPT in Q1 2015 and held it in 2 quarters. The position peaked at $518K in Q4 2015. 160 funds tracked by Wall St. Rank hold ICPT as of Q1 2016.

  • BlueCrest Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • BlueCrest Capital Management sold 3,469 Intercept Pharmaceuticals, Inc. shares in Q1 2016, an estimated $518K.
  • BlueCrest Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • BlueCrest Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $518K in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2016.

Based on BlueCrest Capital Management's 13F filing for Q1 2016, filed 3 May 2016.